Tissue repair

BPC-157

Body Protection Compound-157 · Gastric pentadecapeptide — a tissue-repair peptide with extensive animal data and limited human evidence.

Reviewed by Dr. Sarah Chen, MD, PhD

Gastroenterology · Clinical Pharmacology · Last updated August 2026

Key takeaways

BPC-157 is a synthetic pentadecapeptide derived from human gastric juice with extensive animal data showing tissue-repair effects.
No completed randomized controlled trials of injectable BPC-157 in humans have been published as of this review.
The majority of animal studies originate from a single research group (University of Zagreb), which is a legitimate evidence-quality concern.
An oral formulation Phase II trial for ulcerative colitis was registered but full results remain unpublished.
The unregulated sourcing environment means purity, sterility, and identity of commercially available BPC-157 vary significantly.

Overview

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids, derived from a protective protein found in human gastric juice. It has been studied extensively in animal models since the early 1990s, with published data spanning tendon repair, ligament healing, muscle injury recovery, gastrointestinal protection, and neurological effects.^[1]

The compound has generated significant interest among practitioners evaluating peptide therapeutics, partly because of the volume and consistency of its animal literature, and partly because of its wide commercial availability through compounding pharmacies and research chemical suppliers. This guide evaluates the published evidence without relying on practitioner anecdotes or commercial claims.

Scope of this guide

Mechanism of action

BPC-157’s proposed mechanisms are multi-pathway rather than single-receptor, which complicates clean mechanistic classification. The primary pathways identified in animal studies include:

The glucose-dependent nature of GLP-1-mediated insulin secretion is clinically significant: unlike sulfonylureas, GLP-1 RAs carry minimal hypoglycemia risk as monotherapy because the insulin stimulus diminishes as blood glucose normalizes.

Growth factor upregulation — BPC-157 appears to increase expression of EGF, VEGF, and FGF2, promoting angiogenesis and tissue repair in injured areas.

Nitric oxide system modulation — The peptide interacts with the NO system, which plays roles in vasodilation, inflammation, and tissue healing.

Dopaminergic system interaction — Animal studies suggest effects on the dopamine system, with potential implications for gut-brain axis function.

Cytoprotective effects — Gastric and intestinal protection has been demonstrated across multiple animal models, consistent with the peptide's origin in gastric juice.

This multi-pathway profile is both a source of scientific interest and a reason for caution in extrapolating from animal models. Single-pathway drugs have more predictable pharmacology; multi-pathway compounds require broader safety evaluation.

Published human evidence

As of August 2026, no completed randomized controlled trials of injectable BPC-157 in humans have been published in peer-reviewed journals. The published human evidence consists of:

Oral formulation (Phase II)

A single Phase II trial evaluating oral BPC-157 for ulcerative colitis was registered (NCT number available on ClinicalTrials.gov) and preliminary results were presented at conference proceedings. Full peer-reviewed results have not been published as of this review.

Case series and reports

Several practitioner-reported case series exist in lower-tier journals and conference proceedings. These describe subjective improvements in tendon injuries, joint pain, and gut symptoms. However, they lack controls, blinding, standardized outcome measures, and are subject to significant publication and selection bias.

Animal literature

Extensive. Over 100 published studies across rodent models showing consistent tissue-repair effects in tendons, ligaments, muscle, bone, gastrointestinal mucosa, and peripheral nerves.[3] The consistency of animal data across tissue types is notable, but species-translation assumptions remain unvalidated for injectable use in humans.

Contested evidence: single-lab concentration

The majority of animal studies on BPC-157 originate from a single research group (Sikiric et al., University of Zagreb). While their methodology has been peer-reviewed and partially replicated by independent groups, the concentration of evidence from one laboratory is a legitimate concern in evidence assessment. Independent replication remains limited relative to the breadth of claims.[1]

Related explainers

Tissue repair

Thymosin Beta-4

43-amino acid peptide involved in actin sequestration with wound-healing effects in animal models..

Dermal

GHK-Cu

Copper-binding tripeptide with controlled human data for topical wound healing applications.

References

1
Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." Cell Metab (2018) doi:10.1016/j.cmet.2018.03.001
2
Knudsen LB, Lau J. "The discovery and development of liraglutide and semaglutide." Front Endocrinol (2019) doi:10.3389/fendo.2019.00155
3
Sattar N, et al. "GLP-1 receptor agonists and cardiovascular events: a systematic review and meta-analysis." Lancet Diabetes Endocrinol (2021) doi:10.1016/S2213-8587(21)00203-5
4
Nauck MA, Meier JJ. "Incretin hormones: their role in health and disease." Diabetes Obes Metab (2018) doi:10.1111/dom.13129
5
Frías JP, et al. "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes." N Engl J Med (2021) doi:10.1056/NEJMoa2107519
6
Buckley ST, et al. "Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist." Sci Transl Med (2018) doi:10.1126/scitranslmed.aar7047
7
Wilding JPH, et al. "Once-weekly semaglutide in adults with overweight or obesity (STEP 1)." N Engl J Med (2021) doi:10.1056/NEJMoa2032183
8
Lincoff AM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)." N Engl J Med (2023) doi:10.1056/NEJMoa2307563